Mylan, the maker of the EpiPen, is facing more public backlash after the New York attorney general announced an investigation into the company's contracts with schools. Eric Schneiderman's office is investigating Mylan over “potentially anticompetitive terms” in its sales contracts with school systems in the state. Such terms were discovered in a preliminary review by the attorney general's office, according to a news release. Mylan distributes EpiPens free of charge to more than 65,000 schools nationally. In a statement, Mylan acknowledged that it had previously put a “limited purchase restriction” on schools that wanted to purchase more than the free supply they were allotted, but it no longer exists. The statement also said the program “continues to adhere to all applicable laws and regulations.” A spokeswoman didn't respond when asked what that restriction entailed, but medical news site STAT reported last month that Mylan's previous agreement required that schools agree to “not in the next 12 months purchase any products that are competitive to EpiPen Auto-Injectors.” A Mylan spokesperson told STAT last month that the requirement had been dropped but didn't specify when.